ClinicaliQ Trial Snapshot
- Understanding the Genetic and Biological Factors That Influence Cancer Treatment Response and Resistance in Patients With Advanced Solid Tumours Through Sample Analysis — Recruiting • Oncology • NCT07737509.
- What is being tested: The study investigates genetic mutations and biological factors in cancer cells that predict treatment response and resistance in adults with advanced solid tumours enrolled in early-phase clinical trials.
- Patient eligibility overview: The study includes adult patients with advanced solid cancers who are either being considered for or actively participating in early-phase cancer treatment trials.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The goal of this observational study is to attempt to find altered genetic 'switches' (mutations) in adults with advanced solid cancers who are being considered for, or are participating in, early-phase cancer clinical trials. Research has shown that cancer cells make use of key mutations to 'switch on' their growth, spread, and survival. This study will use this information to evaluate what happens to mutations over time which may help match patients to suitable clinical trials and support the development of more personalised cancer treatments. The main question it aims…
Eligibility Snapshot
- : 1. Histologically, cytologically or biochemically confirmed diagnosis of advanced solid cancer 2. Older than or equal to 18 years of age 3. Patients who are being considered for an early phase clinical trial or who are currently participating in an early phase clinical trial 4. Written (signed and dated) informed consent.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.